Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform f...
Experimental Hematology & Oncology publishes preclinical, basic, patient-oriented and translational research in all areas of hematology and oncology. The ...
Experimental Hematology & Oncology publishes preclinical, basic, patient-oriented and translational research in all areas of hematology and oncology. The ...
Experimental Hematology & Oncology volume 13, Article number: 11 (2024) Cite this article 2816 Accesses 5 Citations 2 Altmetric Metrics details Abstract Background KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, the response to immunotherapy is heterogeneous owing to ...
Experimental Hematology & Oncology publishes preclinical, basic, patient-oriented and translational research in all areas of hematology and oncology. The ...
Experimental Hematology & Oncology volume 13, Article number: 88 (2024) Cite this article 717 Accesses Metrics details Abstract The optimal timing and type of hematopoietic stem cell transplantation (HSCT) for treating peripheral T-cell lymphoma (PTCL) remain controversial. This retrospective real-...
Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non
Experimental Hematology & Oncology volume 13, Article number: 75 (2024) Cite this article 603 Accesses Metrics details Abstract Chimeric antigen receptor (CAR) serves as the foundational element of CAR-T cells. Exogenous CAR molecules can exert functional effects on allogeneic T cells, leading to ...
Metabolic reprogramming is an emerging hallmark of cancer cells, enabling them to meet increased nutrient and energy demands while withstanding the challenging microenvironment. Cancer cells can switch their metabolic pathways, allowing them to adapt to
Experimental Hematology & Oncology volume 13, Article number: 53 (2024) Cite this article 1027 Accesses Metrics details Abstract Increasing evidence supports a role for small extracellular vesicles (sEV, including exosomes) in Diffuse Large B-cell lymphoma (DLBCL) progression and resistance to ...